Medical Director of Pennsylvania's Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath Lung into Medical Practice
SAN ANTONIO, Texas (Feb. 6, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer including CyPath Lung, today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company's Medical and Scientific Advisory Board to provide expert advice and counsel on bioAffinity Technology products and research.
Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath Lung into its practice to aid in the detection of early-stage lung cancer.
"As a clinician, I see hundreds of patients a year who can directly benefit from CyPath Lung, bioAffinity's patient-friendly, noninvasive test for lung cancer. As a researcher, I am excited about the Company's ongoing studies to advance CyPath Lung, as well as noninvasive tests for other lung diseases," Dr. Bansal said. "I look forward to contributing to bioAffinity's innovative approach to lung health by working with the Company's science team and the esteemed physicians and researchers who sit on its advisory board."
Dr. Bansal has extensive experience in minimally invasive pulmonary procedures including navigational and robotic bronchoscopy, endobronchial ultrasound and chest sonography, argon plasma coagulation, cryotherapy, airway stenting, bronchoscopic lung volume reduction and indwelling pleural catheters. A principal investigator of multiple clinical research trials and a journal reviewer for several medical journals, he has been instrumental in developing a comprehensive lung center that allows a rapid assessment and management of healthcare needs based on the population characteristics and available resources. The model has been very successful in bringing advanced pulmonary services, including the latest technology and population health services, including a robust lung cancer screening program, to support the region's clinical needs.
"Dr. Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board. His demonstrated commitment to saving lives and improving patients' quality of life through innovative therapies and his prodigious research are truly impressive," bioAffinity Technologies President and CEO Maria Zannes said. "The caliber of our Advisory Board is a testament to the commitment each physician has placed on bringing breakthrough technology to market in the battle against lung cancer and other diseases of the lung."